Lilly(Eli) & Co
NYSE:LLY 4:00:00 PM EDT
Other Pre-Announcement
Lilly Announces 650,000 Additional Doses Of Neutralizing Antibody Bamlanivimab Purchased By U.S. Government To Treat Covid-19
Published: 12/02/2020 23:14 GMT
Lilly(Eli) & Co (LLY) - Lilly Announces 650,000 Additional Doses of Neutralizing Antibody Bamlanivimab (ly-cov555) Purchased by U.S. Government to Treat Covid-19.
Eli Lilly and Co - Purchase Agreement is for $812.5 Million and Doses Will Be Delivered Through January 31, 2021.
Eli Lilly and Co - Purchase Brings Total Doses Purchased by U.S. Government to 950,000.
Eli Lilly and Co - Purchase Agreement Includes at Least 350,000 of Additional Doses Delivered in December 2020.
Eli Lilly and Co - Bamlanivimab Supply is Expected to Increase Substantially in 2021.
Eli Lilly and Co - Supply of Bamlanivimab is Expected to Increase Substantially in 2021.
Eli Lilly - Estimated Impact of Updated Purchase Agreement to Guidance Range Provided in Earnings Release on Oct 27 is About $500 Million of Additional Revenue.
Eli Lilly - Estimated Impact of Updated Purchase Agreement to Guidance Range Provided in Earnings Release on Oct 27 is About 25 Cents of Additional Eps.
Eli Lilly and Co - Purchase Agreement is for $812.5 Million and Doses Will Be Delivered Through January 31, 2021.
Eli Lilly and Co - Purchase Brings Total Doses Purchased by U.S. Government to 950,000.
Eli Lilly and Co - Purchase Agreement Includes at Least 350,000 of Additional Doses Delivered in December 2020.
Eli Lilly and Co - Bamlanivimab Supply is Expected to Increase Substantially in 2021.
Eli Lilly and Co - Supply of Bamlanivimab is Expected to Increase Substantially in 2021.
Eli Lilly - Estimated Impact of Updated Purchase Agreement to Guidance Range Provided in Earnings Release on Oct 27 is About $500 Million of Additional Revenue.
Eli Lilly - Estimated Impact of Updated Purchase Agreement to Guidance Range Provided in Earnings Release on Oct 27 is About 25 Cents of Additional Eps.